The reverse split is a routine structural adjustment with no fundamental business catalyst. Traders should monitor for any subsequent Nasdaq listing application, business development, or financing news—the split alone does not change the company's operating outlook.
Price Chart
Executive Summary
Galera Therapeutics effected a 1-for-200 reverse stock split, effective July 12, 2026, and began trading split-adjusted on the OTCQB Market on July 13 under the ticker GRTXD. The reverse split is a mechanical capital structure adjustment—no new financing, no business update—and likely reflects an attempt to meet minimum bid price requirements for potential Nasdaq relisting.
Key Facts
- Reverse stock split ratio of 1-for-200 effective July 12, 2026 at 11:59 p.m. ET
- Common stock began trading split-adjusted on OTCQB on July 13, 2026 under ticker GRTXD
- No fractional shares issued; fractional holders receive cash equal to fraction times closing price times 200
- Outstanding options and warrants proportionally adjusted with higher exercise prices
- Shares available under equity plans reduced proportionally
Financial Impact
No financial data provided; reverse split is a capital structure change that does not alter enterprise value, cash, or operations. Cash payouts for fractional shares likely immaterial.
Risk Factors
- OTCQB listing carries higher risk of thin liquidity and reduced institutional coverage
- No new business or financial information provided; stock price may drift in the absence of catalysts
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-301997 |
| Document: d155293dex31.htm | 0001193125-26-301997 |
| Document: 0001193125-26-301997-index-headers.html | 0001193125-26-301997 |
| Document: 0001193125-26-301997-index.html | 0001193125-26-301997 |
| Document: 0001193125-26-301997.txt | 0001193125-26-301997 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 11w ago | EFFECT | — | awaiting T+20 | — | — |
Aug 4, 2026 11w ago | 15-12G | — | awaiting T+20 | — | — |
Aug 3, 2026 12w ago | 8-K | — | awaiting T+20 | — | — |
Jul 13, 2026 15w ago | 8-K | $16.39 | awaiting T+20 | — | — |
Jul 7, 2026 15w ago | 8-K | $17.80 | awaiting T+20 | — | — |
May 21, 2026 22w ago | 425 | $0.1000 $0.0910 | ▼ −9.00% | ▼ −7.58% | — |
May 19, 2026 22w ago | 8-K | $0.1010 $0.0857 | ▲ +15.15% | ▲ +15.89% | — |
Apr 22, 2026 26w ago | 425 | $20.00 $20.20 | ▲ +1.00% | ▼ −3.22% | — |
Apr 22, 2026 26w ago | 425 | $20.00 $20.20 | ▲ +1.00% | ▼ −3.22% | — |
Apr 14, 2026 27w ago | Press Release | $0.0790 $0.1000 | ▼ −26.58% | ▼ −20.29% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers